What is Ptc Therapeutics, Inc. worth?
With the base-case assumptions below, a discounted cash flow model on Ptc Therapeutics, Inc.'s reported free cash flow gives $262.45 per share. The share price was $64.14 on November 10, 2026, 76% below that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 10.0% | 10.0% | $159.34 | +148% |
| Base | 15.0% | 9.0% | $262.45 | +309% |
| Bull | 20.0% | 8.0% | $454.44 | +609% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $340.51 | $364.85 | $394.60 | $431.79 | $479.60 |
| 8.0% | $281.87 | $297.66 | $316.31 | $338.70 | $366.06 |
| 9.0% | $239.20 | $250.00 | $262.45 | $276.98 | $294.15 |
| 10.0% | $206.85 | $214.53 | $223.22 | $233.17 | $244.64 |
| 11.0% | $181.54 | $187.16 | $193.45 | $200.53 | $208.54 |
Where the presets come from
Base: years 1 to 5 grow at Ptc Therapeutics, Inc.'s revenue growth rate over the last 5 fiscal years (35.4% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions